Us Bancorp \De\ Bei Gene, Ltd. Transaction History

Us Bancorp \De\

$82.9 Billion
Q3 2025

A detailed history of Us Bancorp \De\ transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Us Bancorp \De\ holds 1,531 shares of BGNE stock, worth $347,093. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,531

Previous 1,299 17.86%

Holding current value

$347,093

Previous $294,000 18.03%

% of portfolio

0.0%

Previous 0.0%

32 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 10, 2025	BUY	N/A	232 Added 17.86%	1,531 $347,000
Q2 2025 Jul 23, 2025	BUY	N/A	215 Added 19.83%	1,299 $294,000
Q1 2025 May 08, 2025	BUY	$175.1 - $226.71 $60,059 - $77,761	343 Added 46.29%	1,084 $245,000
Q4 2024 Feb 05, 2025	BUY	$174.72 - $246.04 $111,995 - $157,711	641 Added 641.0%	741 $136,000
Q3 2024 Oct 28, 2024	SELL	$143.93 - $224.51 $9,067 - $14,144	-63 Reduced 38.65%	100 $22,000

Q2 2024 Aug 06, 2024	SELL	$129.52 - $174.32 $1,683 - $2,266	-13 Reduced 7.39%	163 $23,000
Q1 2024 May 07, 2024	SELL	$141.8 - $181.47 $17,866 - $22,865	-126 Reduced 41.72%	176 $27,000
Q4 2023 Feb 09, 2024	BUY	$158.67 - $201.58 $5,077 - $6,450	32 Added 11.85%	302 $54,000
Q3 2023 Nov 03, 2023	BUY	$179.87 - $225.13 $11,151 - $13,958	62 Added 29.81%	270 $48,000
Q2 2023 Aug 09, 2023	BUY	$178.3 - $266.78 $3,031 - $4,535	17 Added 8.9%	208 $37,000
Q1 2023 May 09, 2023	SELL	$215.53 - $274.5 $52,158 - $66,429	-242 Reduced 55.89%	191 $41,000
Q4 2022 Feb 13, 2023	SELL	$125.51 - $229.3 $20,081 - $36,688	-160 Reduced 26.98%	433 $95,000
Q3 2022 Oct 27, 2022	SELL	$131.8 - $202.24 $13,048 - $20,021	-99 Reduced 14.31%	593 $81,000
Q2 2022 Aug 01, 2022	SELL	$121.11 - $216.05 $198,862 - $354,754	-1,642 Reduced 70.35%	692 $112,000
Q1 2022 May 11, 2022	SELL	$146.52 - $269.56 $134,944 - $248,264	-921 Reduced 28.29%	2,334 $440,000
Q4 2021 Feb 11, 2022	BUY	$248.56 - $389.34 $1,242 - $1,946	5 Added 0.15%	3,255 $882,000
Q3 2021 Nov 10, 2021	SELL	$249.6 - $403.14 $381,888 - $616,804	-1,530 Reduced 32.01%	3,250 $1.18 Million
Q2 2021 Aug 05, 2021	BUY	$292.75 - $367.01 $55,915 - $70,098	191 Added 4.16%	4,780 $1.64 Million
Q1 2021 Apr 28, 2021	BUY	$260.64 - $382.12 $587,482 - $861,298	2,254 Added 96.53%	4,589 $1.6 Million
Q4 2020 Feb 04, 2021	BUY	$221.31 - $316.61 $11,065 - $15,830	50 Added 2.19%	2,335 $603,000
Q3 2020 Nov 10, 2020	BUY	$189.18 - $286.44 $209,043 - $316,516	1,105 Added 93.64%	2,285 $654,000
Q2 2020 Aug 07, 2020	SELL	$123.9 - $195.41 $28,125 - $44,358	-227 Reduced 16.13%	1,180 $223,000
Q1 2020 May 13, 2020	BUY	$121.84 - $173.19 $31,678 - $45,029	260 Added 22.67%	1,407 $172,000
Q4 2019 Feb 04, 2020	SELL	$115.78 - $208.34 $4,052 - $7,291	-35 Reduced 2.96%	1,147 $190,000
Q3 2019 Nov 08, 2019	SELL	$120.61 - $148.29 $10,372 - $12,752	-86 Reduced 6.78%	1,182 $145,000
Q2 2019 Aug 13, 2019	SELL	$113.99 - $146.86 $4,103 - $5,286	-36 Reduced 2.76%	1,268 $157,000
Q1 2019 May 08, 2019	BUY	$122.82 - $151.83 $100,221 - $123,893	816 Added 167.21%	1,304 $172,000
Q4 2018 Feb 13, 2019	BUY	$107.01 - $175.15 $3,745 - $6,130	35 Added 7.73%	488 $69,000
Q3 2018 Nov 01, 2018	SELL	$152.62 - $189.66 $13,430 - $16,690	-88 Reduced 16.27%	453 $78,000
Q1 2018 May 08, 2018	SELL	$97.41 - $177.22 $60,589 - $110,230	-622 Reduced 53.48%	541 $91,000
Q4 2017 Feb 02, 2018	BUY	$79.6 - $114.73 $2,149 - $3,097	27 Added 2.38%	1,163 $114,000
Q3 2017 Nov 13, 2017	BUY	$66.19 - $103.46 $75,191 - $117,530	1,136	1,136 $118,000

Others Institutions Holding BGNE

# of Institutions

297

Shares Held

30.4M

Call Options Held

147K

Put Options Held

195K

View Full List

About BeiGene, Ltd.

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $23.5B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

More about BGNE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Us Bancorp \De\, based on Form 13F filings with the SEC.

News

Stay updated on Us Bancorp \De\ with notifications on news.

Account